Nine-digit venture rounds for Mirador, Kinaset

A handful of biotechs announced venture fundings as the J.P. Morgan Healthcare Conference began, although many others chose to get their news out early by announcing deals last week.

San Diego-based Mirador Therapeutics Inc. revealed Monday that it had raised $250 million in series B funding during 3Q25. New investors included T. Rowe Price, Adage Capital Partners and affiliates of Fidelity Management & Research Co. Mirador is developing programs for inflammatory bowel disease, rheumatoid arthritis and idiopathic pulmonary fibrosis...